From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. Drug Watch

HIV/AIDS Clinical Care: Drug Watch

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 11-20 of 32 are shown

Label Change for Saquinavir

The new label outlines an increased risk for abnormal heart rhythms when saquinavir is used with ritonavir.

  • October 25, 2010

Heat-Stable Ritonavir Tablet Now Available

The new formulation should improve the usability of boosted PIs in resource-limited settings.

Maraviroc Now Approved for Use in Treatment-Naive HIV-Infected Patients

The new indication maximizes the number of patients who could benefit from maraviroc, but many clinicians and patients will likely opt for agents that are simpler to use.

Etravirine Can Cause Severe Skin and Hypersensitivity Reactions

Severe skin or hypersensitivity reactions should prompt immediate cessation of the drug.

Label Change for Lopinavir/Ritonavir

The revision reflects the drug’s potential for prolonging both the PR interval and the QT interval.

Darunavir Now Approved for Use in Treatment-Naive Patients

Approval is based on a 48-week comparison of ritonavir-boosted darunavir with lopinavir/ritonavir.

Update on Nelfinavir

Nelfinavir can once again be prescribed to children and pregnant women.

  • May 19, 2008

Cefixime Tablets Available in the U.S. Again

Cefixime tablets (Suprax; 400 mg) are now available in the U.S. for the first time since 2002. Cefixime is the only CDC-recommended oral treatment for . . .

  • By ACC Editors
  • May 5, 2008

Abacavir or ddI Therapy and MI Risk?

The FDA has issued an early communication citing the potential association between use of abacavir or ddI and increased risk for myocardial infarction (MI). The . . .

  • April 7, 2008

Label Change for Darunavir

The revision reflects the drug’s potential for hepatotoxicity.

Items 11-20 of 32 are shown

to

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?





Copyright © 2013. Massachusetts Medical Society. All rights reserved.